Roche says gets breakthrough status for Actemra treatment for giant cell arteritis

ZURICH (Reuters) - Roche said the U.S. Food and Drug Administration has granted it breakthrough status to its anti-rheumatoid arthritis medication Actemra/RoActemra (tocilizumab) for giant cell arteritis (GCA).